{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T02:27:40Z","timestamp":1769048860350,"version":"3.49.0"},"reference-count":59,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejinme.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Internal Medicine"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1016\/j.ejim.2021.01.022","type":"journal-article","created":{"date-parts":[[2021,2,6]],"date-time":"2021-02-06T07:39:26Z","timestamp":1612597166000},"page":"51-58","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Prediction and primary prevention of major vascular complications in systemic sclerosis"],"prefix":"10.1016","volume":"87","author":[{"given":"Cosimo","family":"Bruni","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Cometi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2015-765X","authenticated-orcid":false,"given":"Antonietta","family":"Gigante","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edoardo","family":"Rosato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Matucci-Cerinic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.ejim.2021.01.022_bib0001","doi-asserted-by":"crossref","first-page":"137","DOI":"10.5301\/jsrd.5000249","article-title":"Pathogenesis of systemic sclerosis: recent insights of molecular and cellular mechanisms and therapeutic opportunities","volume":"2","author":"Varga","year":"2017","journal-title":"J Scleroderma Rel Disord"},{"issue":"8","key":"10.1016\/j.ejim.2021.01.022_bib0002","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1002\/art.37988","article-title":"Review: evidence that systemic sclerosis is a vascular disease","volume":"65","author":"Matucci-Cerinic","year":"2013","journal-title":"Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.ejim.2021.01.022_bib0003","doi-asserted-by":"crossref","first-page":"e71","DOI":"10.1016\/S2665-9913(19)30144-4","article-title":"The identification and management of interstitial lung disease in systemic sclerosis: evidence-based European consensus statements","volume":"2","author":"Hoffmann-Vold","year":"2020","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.ejim.2021.01.022_bib0004","article-title":"Overall mortality","author":"Moore","year":"2020","journal-title":"J Scleroderma Rel Disord"},{"issue":"1","key":"10.1016\/j.ejim.2021.01.022_bib0005","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1186\/s12931-020-01459-0","article-title":"The need for a holistic approach for SSc-ILD - achievements and ambiguity in a devastating disease","volume":"21","author":"Hoffmann-Vold","year":"2020","journal-title":"Respir Res"},{"issue":"2","key":"10.1016\/j.ejim.2021.01.022_bib0006","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1177\/2397198319826467","article-title":"Raynaud's phenomenon","volume":"4","author":"Herrick","year":"2019","journal-title":"J Scleroderma Rel Disord"},{"issue":"9","key":"10.1016\/j.ejim.2021.01.022_bib0060","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1136\/annrheumdis-2020-217359","article-title":"Quantitative analysis of pulmonary vasculature in systemic sclerosis at spirometry-gated chest CT","volume":"79","author":"Occhipinti","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ejim.2021.01.022_bib0008","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.3389\/fimmu.2018.02045","article-title":"Vascular leaking, a pivotal and early pathogenetic event in systemic sclerosis: should the door be closed?","volume":"9","author":"Bruni","year":"2018","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.ejim.2021.01.022_bib0009","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1186\/s13075-017-1370-5","article-title":"The \"myth\" of loss of angiogenesis in systemic sclerosis: a pivotal early pathogenetic process or just a late unavoidable event?","volume":"19","author":"Matucci-Cerinic","year":"2017","journal-title":"Arthritis Res Ther"},{"issue":"8","key":"10.1016\/j.ejim.2021.01.022_bib0010","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1136\/annrheumdis-2012-203183","article-title":"Increased plasma levels of the VEGF165b splice variant are associated with the severity of nailfold capillary loss in systemic sclerosis","volume":"72","author":"Manetti","year":"2013","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.ejim.2021.01.022_bib0011","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1002\/art.40377","article-title":"Review: defining a unified vascular phenotype in systemic sclerosis","volume":"70","author":"Allanore","year":"2018","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"10.1016\/j.ejim.2021.01.022_bib0012","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1093\/rheumatology\/keu296","article-title":"Digital ulcers as a sentinel sign for early internal organ involvement in very early systemic sclerosis","volume":"54","author":"Bruni","year":"2015","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"10.1016\/j.ejim.2021.01.022_bib0013","doi-asserted-by":"crossref","first-page":"e149","DOI":"10.1016\/S2665-9913(20)30356-8","article-title":"The multifaceted problem of pulmonary arterial hypertension in systemic sclerosis","volume":"3","author":"Bruni","year":"2020","journal-title":"Lancet Rheumatol"},{"issue":"1","key":"10.1016\/j.ejim.2021.01.022_bib0014","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1177\/2397198318758607","article-title":"Kidney involvement in systemic sclerosis: from pathogenesis to treatment","volume":"3","author":"Bruni","year":"2018","journal-title":"J Scleroderma Rel Disord"},{"issue":"1","key":"10.1016\/j.ejim.2021.01.022_bib0016","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1136\/annrheumdis-2014-205295","article-title":"Joint and tendon involvement predict disease progression in systemic sclerosis: a EUSTAR prospective study","volume":"75","author":"Avouac","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.ejim.2021.01.022_bib0017","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1002\/art.10775","article-title":"Predictors of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvement","volume":"48","author":"Steen","year":"2003","journal-title":"Arthritis Rheum"},{"issue":"2 Suppl 76","key":"10.1016\/j.ejim.2021.01.022_bib0018","first-page":"135","article-title":"Effect of dihydropyridine calcium channel blockers and glucocorticoids on the prevention and development of scleroderma renal crisis in an Italian case series","volume":"31","author":"Montanelli","year":"2013","journal-title":"Clin Exp Rheumatol"},{"issue":"8","key":"10.1016\/j.ejim.2021.01.022_bib0019","doi-asserted-by":"crossref","DOI":"10.1111\/micc.12647","article-title":"Monitoring the microcirculation in the diagnosis and follow-up of systemic sclerosis patients: focus on pulmonary and peripheral vascular manifestations","volume":"27","author":"Ruaro","year":"2020","journal-title":"Microcirculation"},{"key":"10.1016\/j.ejim.2021.01.022_bib0020","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.ejim.2019.09.001","article-title":"The Renal Resistive Index in systemic sclerosis: determinants, prognostic implication and proposal for specific age-adjusted cut-offs","volume":"70","author":"Bruni","year":"2019","journal-title":"Eur J Intern Med"},{"issue":"6","key":"10.1016\/j.ejim.2021.01.022_bib0021","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/j.semarthrit.2011.11.005","article-title":"Intrarenal hemodynamic parameters correlate with glomerular filtration rate and digital microvascular damage in patients with systemic sclerosis","volume":"41","author":"Rosato","year":"2012","journal-title":"Semin Arthritis Rheum"},{"issue":"9","key":"10.1016\/j.ejim.2021.01.022_bib0022","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1002\/acr.22309","article-title":"Increased intrarenal arterial stiffness may predict the occurrence of new digital ulcers in systemic sclerosis","volume":"66","author":"Rosato","year":"2014","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.ejim.2021.01.022_bib0023","article-title":"The renal resistive index, a new biomarker for the follow up of vascular modifications in Systemic Sclerosis","author":"Gigante","year":"2020","journal-title":"J Rheumatol"},{"key":"10.1016\/j.ejim.2021.01.022_bib0024","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ejim.2020.05.042","article-title":"Screening for pulmonary arterial hypertension in systemic sclerosis: a systematic literature review","volume":"78","author":"Bruni","year":"2020","journal-title":"Eur J Intern Med"},{"issue":"8","key":"10.1016\/j.ejim.2021.01.022_bib0025","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1136\/annrheumdis-2016-209909","article-title":"Update of EULAR recommendations for the treatment of systemic sclerosis","volume":"76","author":"Kowal-Bielecka","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 1","key":"10.1016\/j.ejim.2021.01.022_bib0026","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2018-000782","article-title":"Systemic sclerosis: state of the art on clinical practice guidelines","volume":"4","author":"Smith","year":"2018","journal-title":"RMD Open"},{"issue":"1","key":"10.1016\/j.ejim.2021.01.022_bib0027","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s10067-019-04564-8","article-title":"Use of vasoactive\/vasodilating drugs for systemic sclerosis (SSc)-related digital ulcers (DUs) in expert tertiary centres: results from the analysis of the observational real-life DeSScipher study","volume":"39","author":"Blagojevic","year":"2020","journal-title":"Clin Rheumatol"},{"issue":"5","key":"10.1016\/j.ejim.2021.01.022_bib0028","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1007\/s10067-013-2172-z","article-title":"Low occurrence of digital ulcers in scleroderma patients treated with bosentan for pulmonary arterial hypertension: a retrospective case-control study","volume":"32","author":"Cozzi","year":"2013","journal-title":"Clin Rheumatol"},{"issue":"1 suppl","key":"10.1016\/j.ejim.2021.01.022_bib0029","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1177\/0300060515593257","article-title":"Beneficial effects of long-term treatment with bosentan on the development of pulmonary arterial hypertension in patients with systemic sclerosis","volume":"44","author":"Murdaca","year":"2016","journal-title":"J Int Med Res"},{"issue":"3","key":"10.1016\/j.ejim.2021.01.022_bib0030","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1093\/rheumatology\/ket424","article-title":"In systemic sclerosis patients, bosentan is safe and effective for digital ulcer prevention and it seems to attenuate the development of pulmonary arterial hypertension","volume":"53","author":"Romaniello","year":"2014","journal-title":"Rheumatology (Oxford)"},{"issue":"12","key":"10.1016\/j.ejim.2021.01.022_bib0031","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0243651","article-title":"Effect of bosentan in pulmonary hypertension development in systemic sclerosis patients with digital ulcers","volume":"15","author":"Castellvi","year":"2020","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.ejim.2021.01.022_bib0032","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s10067-015-3119-3","article-title":"Combination therapy with Bosentan and Sildenafil improves Raynaud's phenomenon and fosters the recovery of microvascular involvement in systemic sclerosis","volume":"35","author":"Bellando-Randone","year":"2016","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.ejim.2021.01.022_bib0033","article-title":"The incidence rate of pulmonary arterial hypertension and scleroderma renal crisis in systemic sclerosis patients with digital ulcers on endothelin antagonist receptors (ERAs) and phosphodiesterase-5 inhibitors (PDE5i)","author":"Pestana-Fernandez","year":"2020","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"10.1016\/j.ejim.2021.01.022_bib0034","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1007\/s10067-018-4043-0","article-title":"The safety of iloprost in systemic sclerosis in a real-life experience","volume":"37","author":"Bellando-Randone","year":"2018","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.ejim.2021.01.022_bib0035","doi-asserted-by":"crossref","DOI":"10.1007\/s10238-019-00553-y","article-title":"Iloprost use and medical management of systemic sclerosis-related vasculopathy in Italian tertiary referral centers: results from the PROSIT study","author":"Negrini","year":"2019","journal-title":"Clin Exp Med"},{"issue":"5","key":"10.1016\/j.ejim.2021.01.022_bib0036","first-page":"503","article-title":"Effects of long-term cyclic iloprost therapy in systemic sclerosis with Raynaud's phenomenon. A randomized, controlled study","volume":"19","author":"Scorza","year":"2001","journal-title":"Clin Exp Rheumatol"},{"issue":"2","key":"10.1016\/j.ejim.2021.01.022_bib0037","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/s00296-006-0222-4","article-title":"Does cyclically iloprost infusion prevent severe isolated pulmonary hypertension in systemic sclerosis? Preliminary results","volume":"27","author":"Caramaschi","year":"2006","journal-title":"Rheumatol Int"},{"issue":"10","key":"10.1016\/j.ejim.2021.01.022_bib0038","first-page":"1944","article-title":"Effect of iloprost infusion on the resistance index of renal vessels of patients with systemic sclerosis","volume":"24","author":"Scorza","year":"1997","journal-title":"J Rheumatol"},{"issue":"11","key":"10.1016\/j.ejim.2021.01.022_bib0039","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1002\/art.1780331105","article-title":"Diffusing capacity of the lung and nifedipine in systemic sclerosis","volume":"33","author":"Sfikakis","year":"1990","journal-title":"Arthritis Rheum"},{"issue":"12","key":"10.1016\/j.ejim.2021.01.022_bib0040","doi-asserted-by":"crossref","first-page":"2646","DOI":"10.1002\/1529-0131(199912)42:12<2646::AID-ANR21>3.0.CO;2-T","article-title":"Losartan therapy for Raynaud's phenomenon and scleroderma: clinical and biochemical findings in a fifteen-week, randomized, parallel-group, controlled trial","volume":"42","author":"Dziadzio","year":"1999","journal-title":"Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.ejim.2021.01.022_bib0041","doi-asserted-by":"crossref","first-page":"530","DOI":"10.3109\/s10165-009-0199-4","article-title":"Long-term beneficial effects of statins on vascular manifestations in patients with systemic sclerosis","volume":"19","author":"Kuwana","year":"2009","journal-title":"Mod Rheumatol"},{"issue":"9","key":"10.1016\/j.ejim.2021.01.022_bib0042","first-page":"1801","article-title":"Statins: potentially useful in therapy of systemic sclerosis-related Raynaud's phenomenon and digital ulcers","volume":"35","author":"Abou-Raya","year":"2008","journal-title":"J Rheumatol"},{"issue":"9","key":"10.1016\/j.ejim.2021.01.022_bib0043","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/j.autrev.2018.03.012","article-title":"Therapy of scleroderma renal crisis: state of the art","volume":"17","author":"Zanatta","year":"2018","journal-title":"Autoimmun Rev"},{"issue":"1","key":"10.1016\/j.ejim.2021.01.022_bib0044","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s13075-020-2141-2","article-title":"ACE inhibitors in SSc patients display a risk factor for scleroderma renal crisis-a EUSTAR analysis","volume":"22","author":"Butikofer","year":"2020","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"10.1016\/j.ejim.2021.01.022_bib0045","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1186\/s12882-019-1467-y","article-title":"Systemic sclerosis medications and risk of scleroderma renal crisis","volume":"20","author":"Gordon","year":"2019","journal-title":"BMC Nephrol"},{"issue":"5","key":"10.1016\/j.ejim.2021.01.022_bib0046","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.semarthrit.2013.09.008","article-title":"International Scleroderma Renal Crisis Study I. Exposure to ACE inhibitors prior to the onset of scleroderma renal crisis-results from the International Scleroderma Renal Crisis Survey","volume":"43","author":"Hudson","year":"2014","journal-title":"Semin Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.ejim.2021.01.022_bib0047","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s00296-016-3632-y","article-title":"Arterial hypertension treated with angiotensin converting enzyme inhibitors and glucocorticoids are independent risk factors associated with decreased glomerular filtration rate in systemic sclerosis","volume":"37","author":"Ostojic","year":"2017","journal-title":"Rheumatol Int"},{"issue":"7","key":"10.1016\/j.ejim.2021.01.022_bib0048","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1177\/0003319711432861","article-title":"The association of Raynaud syndrome with beta-blockers: a meta-analysis","volume":"63","author":"Mohokum","year":"2012","journal-title":"Angiology"},{"issue":"3","key":"10.1016\/j.ejim.2021.01.022_bib0049","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1136\/ard.43.3.407","article-title":"A controlled trial of antihypertensive therapy in systemic sclerosis (scleroderma)","volume":"43","author":"Fries","year":"1984","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"10.1016\/j.ejim.2021.01.022_bib0050","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1002\/art.38098","article-title":"2013 classification criteria for systemic sclerosis: an American College of Rheumatology\/European League against Rheumatism collaborative initiative","volume":"65","author":"van den Hoogen","year":"2013","journal-title":"Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.ejim.2021.01.022_bib0051","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1080\/1744666X.2017.1263153","article-title":"Use of biologics and other novel therapies for the treatment of systemic sclerosis","volume":"13","author":"Bruni","year":"2017","journal-title":"Expert Rev Clin Immunol"},{"issue":"12","key":"10.1016\/j.ejim.2021.01.022_bib0052","doi-asserted-by":"crossref","first-page":"3731","DOI":"10.1093\/rheumatology\/keaa136","article-title":"Safety and efficacy of rituximab biosimilar (CT-P10) in systemic sclerosis: an Italian multicentre study","volume":"59","author":"Campochiaro","year":"2020","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"10.1016\/j.ejim.2021.01.022_bib0053","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/j.semarthrit.2019.12.004","article-title":"Safety and effectiveness of abatacept in systemic sclerosis: the EUSTAR experience","volume":"50","author":"Castellvi","year":"2020","journal-title":"Semin Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.ejim.2021.01.022_bib0054","doi-asserted-by":"crossref","first-page":"115","DOI":"10.5301\/jsrd.5000236","article-title":"Defining skin ulcers in systemic sclerosis: systematic literature review and proposed World Scleroderma Foundation (WSF) definition","volume":"2","author":"Suliman","year":"2017","journal-title":"J Scleroderma Relat Disord"},{"issue":"1","key":"10.1016\/j.ejim.2021.01.022_bib0055","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1136\/annrheumdis-2013-203889","article-title":"Evidence for oesophageal and anorectal involvement in very early systemic sclerosis (VEDOSS): report from a single VEDOSS\/EUSTAR centre","volume":"74","author":"Lepri","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"10.1016\/j.ejim.2021.01.022_bib0056","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.3899\/jrheum.091165","article-title":"Characteristics of joint involvement and relationships with systemic inflammation in systemic sclerosis: results from the EULAR Scleroderma Trial and Research Group (EUSTAR) database","volume":"37","author":"Avouac","year":"2010","journal-title":"J Rheumatol"},{"issue":"9","key":"10.1016\/j.ejim.2021.01.022_bib0057","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1136\/annrheumdis-2019-215145","article-title":"Predictors of disease worsening defined by progression of organ damage in diffuse systemic sclerosis: a European Scleroderma Trials and Research (EUSTAR) analysis","volume":"78","author":"Becker","year":"2019","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"10.1016\/j.ejim.2021.01.022_bib0058","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1136\/annrheumdis-2018-213201","article-title":"Prediction of progression of interstitial lung disease in patients with systemic sclerosis: the SPAR model","volume":"77","author":"Wu","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.ejim.2021.01.022_bib0059","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1177\/2397198319886496","article-title":"Patient-reported outcome instruments in clinical trials of systemic sclerosis","volume":"5","author":"Pauling","year":"2020","journal-title":"J Scleroderma Relat Disord"},{"issue":"1","key":"10.1016\/j.ejim.2021.01.022_bib0061","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10067-019-04834-5","article-title":"Recent advances steer the future of systemic sclerosis toward precision medicine","volume":"39","author":"Lepri","year":"2020","journal-title":"Clin Rheumatol"}],"container-title":["European Journal of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620521000224?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620521000224?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T09:34:47Z","timestamp":1760607287000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0953620521000224"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":59,"alternative-id":["S0953620521000224"],"URL":"https:\/\/doi.org\/10.1016\/j.ejim.2021.01.022","relation":{},"ISSN":["0953-6205"],"issn-type":[{"value":"0953-6205","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prediction and primary prevention of major vascular complications in systemic sclerosis","name":"articletitle","label":"Article Title"},{"value":"European Journal of Internal Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejim.2021.01.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}